SEB Asset Management AB Acquires Shares of 272,654 NewAmsterdam Pharma Company N.V. $NAMS

SEB Asset Management AB bought a new position in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) in the first quarter, Holdings Channel.com reports. The fund bought 272,654 shares of the company’s stock, valued at approximately $8,728,000.

A number of other hedge funds have also modified their holdings of the business. Duquesne Family Office LLC lifted its stake in shares of NewAmsterdam Pharma by 131.2% in the third quarter. Duquesne Family Office LLC now owns 1,923,700 shares of the company’s stock worth $54,710,000 after buying an additional 1,091,525 shares in the last quarter. Castle Hook Partners LP acquired a new stake in NewAmsterdam Pharma in the 4th quarter valued at about $38,062,000. Adage Capital Partners GP L.L.C. lifted its stake in NewAmsterdam Pharma by 54.5% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock worth $54,566,000 after purchasing an additional 1,062,359 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in NewAmsterdam Pharma by 96.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,725,662 shares of the company’s stock worth $60,536,000 after purchasing an additional 845,110 shares in the last quarter. Finally, Wellington Management Group LLP boosted its holdings in shares of NewAmsterdam Pharma by 21.0% during the 3rd quarter. Wellington Management Group LLP now owns 4,020,126 shares of the company’s stock worth $114,332,000 after purchasing an additional 697,129 shares during the last quarter. 89.89% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at NewAmsterdam Pharma

In other news, CAO Louise Frederika Kooij sold 65,000 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $35.69, for a total transaction of $2,319,850.00. Following the completion of the transaction, the chief accounting officer directly owned 24,353 shares in the company, valued at approximately $869,158.57. This represents a 72.75% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 12.74% of the stock is currently owned by company insiders.

NewAmsterdam Pharma Price Performance

NewAmsterdam Pharma stock opened at $32.34 on Wednesday. The firm has a 50 day simple moving average of $33.17 and a 200-day simple moving average of $32.95. The stock has a market cap of $3.78 billion, a price-to-earnings ratio of -18.07 and a beta of 0.08. NewAmsterdam Pharma Company N.V. has a 1-year low of $21.14 and a 1-year high of $42.21.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings results on Tuesday, March 31st. The company reported ($0.40) EPS for the quarter. The firm had revenue of $3.04 million for the quarter. NewAmsterdam Pharma had a negative net margin of 943.23% and a negative return on equity of 26.49%. Equities analysts expect that NewAmsterdam Pharma Company N.V. will post -1.78 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on NAMS shares. Jefferies Financial Group restated a “buy” rating and issued a $45.00 price target on shares of NewAmsterdam Pharma in a research report on Monday. Royal Bank Of Canada lifted their price objective on NewAmsterdam Pharma from $47.00 to $51.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Friday. BMO Capital Markets began coverage on NewAmsterdam Pharma in a report on Monday. They issued an “outperform” rating and a $58.00 target price for the company. Finally, Wall Street Zen raised NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, NewAmsterdam Pharma presently has a consensus rating of “Moderate Buy” and an average target price of $49.42.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.